No Sex-Associated Differences Observed in Response to Rheumatoid Arthritis Treatment

The Best Face Wash For Psoriasis
August 2, 2018
Treating Pancreatic Cancer During Pregnancy 
August 3, 2018
Show all

No Sex-Associated Differences Observed in Response to Rheumatoid Arthritis Treatment

Both genders respond similarly to rheumatoid arthritis medications.

Although men with rheumatoid arthritis (RA) are often prescribed different initial treatments compared with women with RA, there are no differences in response to treatment between the sexes, according to results published in The Journal of Rheumatology.

The study included participants with RA starting different antirheumatic treatments from the international, observational METEOR register (n=5535). The researchers compared response to treatment using visits from the start of the first disease-modifying antirheumatic drug (DMARD) therapy until the first DMARD switch or until the end of follow-up. The researchers calculated the effect of sex on time to switch from first to second treatment and whether men and women responded differently to treatments.

Women with RA (n=4393) were more likely to start treatment with hydroxychloroquine as monotherapy or in combination with methotrexate or a glucocorticoid. Men with RA (n=1142), on the other hand, were more likely to start treatment with methotrexate or sulfasalazine.

The time to a DMARD switch was shorter for women with RA (median, 175 days; n=2756) compared with men (median, 200 days; n=647).

Differences in improvement in Disease Activity Score (DAS) over time was negligible between men (β= –0.69; 95% CI, –0.75 to –0.62 per year) and women (β= –0.58; 95% CI, –0.62 to –0.55 per year).

Read on: No Sex-Associated Differences Observed in Response to Rheumatoid Arthritis Treatment

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.